Amgen Is Still ‘A Biotech At Heart’
Exclusive Interview With Kave Niksefat
Executive Summary
Head of Amgen’s inflammation business, Kave Niksefat, gives insight into how the 40-year-old biotech maintains its culture of innovation and avoids falling into the “trap” of bureaucracy.
You may also be interested in...
Amgen Eschews Some Of Its BiTEs, But Otezla Spurs Growth
Without Otezla’s $2.2bn in 2020 sales, Amgen’s full-year revenue would have been slightly lower than in 2019, which is why all eyes are on the company’s R&D programs and near-term approvals.
While Amgen Sees Success For Two Growth Drivers, Headwinds Remain
Scrip discussed key wins for sotorasib in lung cancer and tezepelumab in asthma with Amgen executives Murdo Gordon and David Reese, but COVID-19 and other challenges are looming.
Price Inflation Rebates And The Spectre Of 100% Discounts In Medicare Part D
Medicaid programs are essentially getting Humira for free, in large part because of price inflation rebates, according to estimates by Bernstein analysts. Legislation pending in the US Senate wants to bring that dynamic to Medicare.